Cambrex Stock Gaps Down On Today's Open (CBM)

NEW YORK ( TheStreet) -- Shares of Cambrex Corporation (NYSE: CBM) were gapping down Tuesday morning with an open price 12.5% lower than Monday's closing price. The stock closed at $8.02 Monday and opened today's trading at $7.02.

The average volume for Cambrex has been 291,200 shares per day over the past 30 days. Cambrex has a market cap of $227.3 million and is part of the health care sector and drugs industry. Shares are up 11.7% year to date as of the close of trading on Monday.

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics. It primarily involves in the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The company has a P/E ratio of 15.3, below the average drugs industry P/E ratio of 15.4 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Cambrex as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and attractive valuation levels. However, as a counter to these strengths, we find that the company has not been very careful in the management of its balance sheet. You can view the full Cambrex Ratings Report.

Get more investment ideas from our investment research center.

Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)